Shares of Natera, Inc. (NASDAQ:NTRA) have been assigned a consensus rating of “Hold” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.00.

Several research firms have recently issued reports on NTRA. Morgan Stanley reaffirmed an “overweight” rating and set a $16.00 price objective (up from $13.00) on shares of Natera in a research report on Friday, October 6th. Zacks Investment Research raised Natera from a “sell” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Wednesday, October 11th. Robert W. Baird reaffirmed a “buy” rating on shares of Natera in a research report on Tuesday, October 24th. Cowen reaffirmed a “buy” rating and set a $14.00 price objective on shares of Natera in a research report on Friday, September 1st. Finally, BidaskClub raised Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd.

Natera (NTRA) traded down $0.22 during trading hours on Monday, hitting $9.51. The stock had a trading volume of 105,300 shares, compared to its average volume of 194,146. Natera has a twelve month low of $7.35 and a twelve month high of $14.76. The company has a quick ratio of 1.75, a current ratio of 1.85 and a debt-to-equity ratio of 2.43.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.04). The business had revenue of $56.66 million for the quarter, compared to analyst estimates of $55.31 million. Natera had a negative return on equity of 197.09% and a negative net margin of 62.34%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.50) earnings per share. research analysts forecast that Natera will post -2.15 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Natera by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 235,287 shares of the medical research company’s stock valued at $2,086,000 after purchasing an additional 10,813 shares during the period. Contrarius Investment Management Ltd boosted its position in shares of Natera by 1.4% in the 2nd quarter. Contrarius Investment Management Ltd now owns 480,944 shares of the medical research company’s stock valued at $5,223,000 after purchasing an additional 6,491 shares during the period. Tygh Capital Management Inc. acquired a new stake in shares of Natera in the 3rd quarter valued at about $2,794,000. Macquarie Group Ltd. boosted its position in shares of Natera by 112.3% in the 2nd quarter. Macquarie Group Ltd. now owns 1,061,880 shares of the medical research company’s stock valued at $11,532,000 after purchasing an additional 561,659 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Natera by 12.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,261,052 shares of the medical research company’s stock valued at $24,555,000 after purchasing an additional 253,344 shares during the period. 66.19% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/11/natera-inc-ntra-receives-average-rating-of-hold-from-analysts.html.

Natera Company Profile

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.